GreenLight Biosciences Holdings

NasdaqGM:GRNA Stock Report

Market Cap: US$45.4m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

GreenLight Biosciences Holdings Management

Management criteria checks 3/4

GreenLight Biosciences Holdings' CEO is Andrey Zarur, appointed in Aug 2008, they has a tenure of 14.92 years. Their total yearly compensation is $576.56K , comprised of 99.7% salary and 0.3% bonuses, including company stock and options. They directly owns 0.59% of the company’s shares, worth $268.37K. The average tenure of the management team and the board of directors is 1.3 years and 4.4 years respectively.

Key information

Andrey Zarur

Chief executive officer

US$576.6k

Total compensation

CEO salary percentage99.73%
CEO tenure14.9yrs
CEO ownership0.6%
Management average tenure1.3yrs
Board average tenure4.4yrs

Recent management updates

Recent updates

Seeking Alpha • Oct 12

GreenLight Biosciences cutting 25% of staff as part of realignment

GreenLight Biosciences (NASDAQ:GRNA)is eliminating 25% of its workforce as part of a realignment to support R&D in its research, development and commercialization of its plant health and human health pipelines. On the human health front, the company will focus on proof of concept of its technology platform with its COVID vaccine and advancing ITS shingles program in collaboration with THE Serum Institute of India. Regarding plant health, GreenLight (GRNA) will continue to advance fungicides and insecticides in its pipeline.
Seeking Alpha • Aug 12

GreenLight Biosciences launches $109M in financing

GreenLight Biosciences (NASDAQ:GRNA) announced a private placement of ~$109M; financing includes participation from new and existing institutional investors. The company has agreed to sell ~27.8M shares to a select group of institutional and accredited investors at $3.92/share. The company plans to use the net proceeds from the financing to advance its development of research and commercial programs and for working capital and general corporate purposes. The proceeds from this financing, combined with current cash and equivalents, is expected to be sufficient to fund operations through the 1H23. Shares trading 2.8% higher premarket.
Seeking Alpha • Aug 01

GreenLight Biosciences, Samsung Biologics complete commercial-scale engineering run for mRNA COVID-19 vaccine

GreenLight Biosciences (NASDAQ:GRNA) and partner Samsung Biologics announced the successful completion of the first commercial-scale engineering run for the companies' mRNA COVID-19 vaccine. After the announcement of the partnership, technology transfer and scale-up from the lab bench to Samsung's commercial facility was completed in seven months. The companies said commercial-scale run has demonstrated production—in a single facility—of both Drug Substance and LNP formulation, allowing the production of bulk Drug Product. (GRNA) is up 3.6%.
Seeking Alpha • Apr 05

GreenLight Biosciences: Synthesizing Cell-Free RNA

GreenLight Biosciences makes affordable and accessible RNA products for human health and agriculture. The company’s cell-free RNA manufacturing platform allows for cost-effective and scalable production of RNA. The company became a publicly listed and Public-Benefit Corporation following a business combination in February 2022.

CEO Compensation Analysis

How has Andrey Zarur's remuneration changed compared to GreenLight Biosciences Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2023n/an/a

-US$157m

Dec 31 2022US$577kUS$575k

-US$167m

Sep 30 2022n/an/a

-US$163m

Jun 30 2022n/an/a

-US$154m

Mar 31 2022n/an/a

-US$129m

Dec 31 2021US$728kUS$500k

-US$112m

Sep 30 2021n/an/a

-US$86m

Jun 30 2021n/an/a

-US$89m

Mar 31 2021n/an/a

-US$75m

Dec 31 2020US$2mUS$450k

-US$53m

Compensation vs Market: Andrey's total compensation ($USD576.56K) is about average for companies of similar size in the US market ($USD749.31K).

Compensation vs Earnings: Andrey's compensation has been consistent with company performance over the past year.

CEO

Andrey Zarur (52 yo)

14.9yrs
Tenure
US$576,561
Compensation

Dr. Andrey Juan Zarur, Ph.D. Co-founded GreenLight Biosciences Holdings (aka GreenLight Biosciences, Inc) in 2008 and serves as its President and Chief Executive Officer since August 2008. Dr. Zarur serves...

Leadership Team

NamePositionTenureCompensationOwnership
Andrey Zarur
Co-Founder14.9yrsUS$576.56k0.59%
$ 268.4k
Susan Keefe
CFO & Interim Chief Accounting Officer4.2yrsUS$1.28m0%
$ 0
Carole Cobb
Chief Operating Officer7.5yrsUS$1.30m0%
$ 0
Marta Ortega-Valle
Co-founder and Chief Sustainability & Strategy Officerless than a yearno data0.020%
$ 8.9k
Drew Cunningham
Chief Technology Officer1.3yrsno datano data
Nina Thayer
General Counselless than a yearno datano data
Thomas Crampton
Senior VP & Head of Corporate Affairs2.5yrsno datano data
David Kennedy
Advisorno datano data0%
$ 0
Mark Singleton
Chief Commercial Officer & General Manager of Plant Health2.4yrsno data0%
$ 0
Shelly Karuna
Chief Medical Officerless than a yearno datano data
Kimberly Warren
Chief Business Officerless than a yearno datano data
Nicholas Skizim
Rollover Investorless than a yearno data0.018%
$ 8.1k
1.3yrs
Average Tenure
52yo
Average Age

Experienced Management: GRNA's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Andrey Zarur
Co-Founder14.9yrsUS$576.56k0.59%
$ 268.4k
Eric O'Brien
Independent Director4.1yrsUS$293.23k0%
$ 0
Charles Leland Cooney
Independent Chairman of the Board12.6yrsUS$429.53k0.20%
$ 91.5k
Ganesh Kishore
Independent Director8.5yrsUS$293.23k0%
$ 0
Theodore Ashburn
Advisorno datano datano data
Colin Steen
Board Observer4.2yrsno datano data
Martha Schlicher
Independent Director5.4yrsUS$293.23k0%
$ 0
Christopher Abbott
Board Observer4.2yrsno datano data
Mark Cupta
Board Observer4.2yrsno datano data
Luc Debruyne
Advisorno datano datano data
Matthew Walker
Independent Director4.6yrsUS$293.23k0.042%
$ 19.1k
David Russell
Board Observer4.2yrsno datano data
4.4yrs
Average Tenure
57.5yo
Average Age

Experienced Board: GRNA's board of directors are considered experienced (4.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/07/25 09:55
End of Day Share Price 2023/07/21 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

GreenLight Biosciences Holdings is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert BurlesonCanaccord Genuity